| 摘要 |
The present invention includes transgenic animals, such as transgenic mice, that express a dominant-negative form of RAG-I during the transitional stage of B lymphocyte development, permitting initial antigen receptor gene rearrangement but blocking receptor editing and/or receptor revision that occurs during later periods in development. In one aspect the transgenic animal includes in its genome an exogenous polynucleotide includes a coding sequence encoding a catalytically defective RAG-I polypeptide, or an analog thereof. The present invention also provides methods of making and using such transgenic animals.
|
